论文部分内容阅读
天津医药集团旗下中新药业集团股份有限公司今年以来工业板块深化大品种战略,商业板块积极进行产品结构调整,同时不断加大科技投入,为企业发展带来强劲发展动力。记者昨天从中新药业集团获悉,今年前三季度,中新药业实现工业总产值同比增长23%,销售同比增长27.46%,主营利润同比增长28.64%。其中新产品产值达8.2亿元,同比增长超50%。中新药业龙头产品速效救心丸今年前三季度的销售收入完成年计划的81.47%,同比增长
Since the beginning of this year, Zhongxin Pharmaceutical Group Co., Ltd., a subsidiary of Tianjin Pharmaceutical Group, has deepened its large-scale industrial strategy and the commercial sector has actively adjusted its product mix. At the same time, it has continuously increased investment in science and technology and brought strong impetus to the development of the Company. Reporter learned from Zhongxin Pharmaceutical Group yesterday that in the first three quarters of this year, the total industrial output value of Sinopharm Group increased by 23% over the same period of last year with a year-on-year increase of 27.46% and the main profit increased by 28.64% over the same period of last year. Among them, the output value of new products reached 820 million yuan, up by 50% over the same period of last year. In the first three quarters of this year, the sales revenue of China Pharmaceutical Daily, the leading new pharmaceutical product, was 81.47% of the annual plan, an increase over the same period of previous year